Publication Name	World Journal of Clinical Oncology
Manuscript ID	115789
Country	Morocco

Category	Immunology
Manuscript Type	Letter to the Editor
Article Title	Ectonucleoside triphosphate diphosphohydrolase 6: A double-edged sword in cancer prognosis and therapy
Manuscript Source	Invited Manuscript
All Author List	Abdellatif Bouayad
Funding Agency and Grant Number
Corresponding Author	Abdellatif Bouayad, Associate Professor, MD, Department of Immunology, Faculty of Medicine and Pharmacy Oujda, Mohammed First University, Mohammed V Avenue, Oujda-Angad 60049, Oriental, Morocco. abdellatifbouayad@hotmail.fr
Key Words	Ectonucleoside triphosphate diphosphohydrolase 6; Cancer; Prognosis; Therapy; Antitumor immunity
Core Tip	Ectonucleoside triphosphate diphosphohydrolase 6 (ENTPD6) has dual effects on cancer development and progression, influencing immune surveillance and immune evasion through tumor microenvironment modulation. It serves as a promising novel molecular biomarker for prognosis and for predicting cancer therapy responses. Furthermore, ENTPD6-derived neopeptide vaccines, as well as adoptive T-cell transfer using T cells engineered with T-cell receptors targeting ENTPD6, may constitute promising strategies in cancer immunotherapy.
Citation	Bouayad A. Ectonucleoside triphosphate diphosphohydrolase 6: A double-edged sword in cancer prognosis and therapy. World J Clin Oncol 2025; In press

Received	2025-10-27 03:28
Peer-Review Started	2025-10-27 03:28
To Make the First Decision
Return for Revision	2025-10-30 08:52
Revised	2025-10-30 14:51
Second Decision	2025-11-20 02:37
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2025-11-20 05:53
Articles in Press	2025-11-20 05:53
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript

ISSN	2218-4333 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com